Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Liminal BioSciences Inc. (T:LMNL)

Business Focus: Biotechnology & Medical Research

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for LMNL within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jul 02, 2020 11:16 ET
Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy
LAVAL, QC and CAMBRIDGE, England, July 2, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced that Prometic Plasma Resources, a subsidiary of Liminal BioSciences Inc., has joined the CoVIg-19 Plasma Alliance to contribute to the acceleration of the development of a potential new therapy for COVID-19....
Read full article
Jul 02, 2020 11:16 ET
Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy
LAVAL, QC and CAMBRIDGE, England, July 2, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced that Prometic Plasma Resources, a subsidiary of Liminal BioSciences Inc., has joined the CoVIg-19 Plasma Alliance to contribute to the acceleration of the development of a potential new therapy for COVID-19.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.59
--
--
Price to Sales - TTM
104.24
10.96
8.60
Price to Book - most recent quarter
4.97
4.91
2.67
Price to Cash Flow per share - TTM
--
19.25
12.30
Price to Free Cash Flow per share - TTM
--
54.78
22.04
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jun 30, 202020,202-1,855
Jun 15, 202022,057-7,620
May 31, 202029,677-3,344
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Liminal BioSciences Inc., formerly Prometic Life Sciences Inc., is a Canada-based biopharmaceutical company. The Company is focused on developing a pipeline of small molecule therapeutics to treat patients with liver, respiratory and kidney disease, with a focus on rare or orphan diseases. It operates through three segments: Small Molecule Therapeutics Segment, Plasma-derived Therapeutics Segment and Bioseparations segment. The Small Molecule Therapeutics Segment is a small-molecule drug development business. The Plasma-derived Therapeutics Segment includes its plasma-derived therapeutics platform, which enables the development of its pipeline of biopharmaceutical candidates. Bioseparations segment is engaged in bioseparation, specifically for purification of biologics and the elimination of pathogens. Its product candidates include PBI-4050, PBI-4547, Ryplazim IV and Inter Alpha Inhibitor Protein (IAIP).

See business summary

 

Twitter

Search (past week) for $LMNL.CA

  • No tweets found